Corient Capital Partners’s DexCom DXCM Stock Holding History

Corient Capital Partners’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$480K	Buy	6,444 +489	+8%	+$41.4K	0.04%	348
2022 Q2	$444K	Sell	5,955 -373	-6%	-$34K	0.03%	372
2022 Q1	$809K	Buy	6,328 +420	+7%	+$45.9K	0.05%	281
2021 Q4	$793K	Buy	5,908 +208	+4%	+$29.9K	0.05%	277
2021 Q3	$779K	Buy	5,700 +216	+4%	+$27.2K	0.06%	261
2021 Q2	$585K	Buy	5,484 +572	+12%	+$54.9K	0.04%	326
2021 Q1	$442K	Buy	4,912 +440	+10%	+$41.3K	0.04%	340
2020 Q4	$413K	Sell	4,472 -2,556	-36%	-$228K	0.04%	310
2020 Q3	$725K	Sell	7,028 -464	-6%	-$48.5K	0.08%	204
2020 Q2	$759K	Buy	7,492 +3,608	+93%	+$323K	0.09%	197
2020 Q1	$261K	Buy	3,884 +208	+6%	+$12.9K	0.04%	318
2019 Q4	$201K	Buy	+3,676	New	+$174K	0.03%	431

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Corient Capital Partners's DXCM Position: Q3 2022 in Review

Corient Capital Partners increased its DexCom (DXCM) stake by 8.2% in Q3 2022, buying an estimated $41.4K and bringing the position to 6,444 shares worth $480K. The position accounts for 0.04% of the portfolio, ranked #348.

Corient Capital Partners first reported a position in DXCM in Q4 2019 and has held it in 12 quarters since. The position peaked at $809K in Q1 2022. 794 funds tracked by Wall St. Rank hold DXCM as of Q3 2022.

Corient Capital Partners held 6,444 shares of DexCom worth $480K as of Q3 2022.
Corient Capital Partners bought 489 DexCom shares in Q3 2022, an estimated $41.4K.
DexCom made up 0.04% of Corient Capital Partners's portfolio in Q3 2022, its #348 holding.
Corient Capital Partners first reported a position in DexCom in Q4 2019 and has held it in 12 quarters since.
Corient Capital Partners's DexCom position peaked at $809K in Q1 2022.
794 funds tracked by Wall St. Rank held DexCom as of Q3 2022.

Based on Corient Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.